Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity.
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
04
2020
revised:
31
07
2020
accepted:
25
11
2020
pubmed:
3
12
2020
medline:
15
12
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
The impact of omega (ω)-3 fatty acids on prostate cancer is controversial in epidemiological studies but experimental studies suggest a protective effect. However, little is known about the mechanism of action. Here, we studied the effects of purified fatty acid molecules on prostate tumor progression using the TRAMP-C2 syngeneic immunocompetent mouse model. Compared with ω-6 or ω-9-supplemented animals, we observed that late-stage prostate tumor growth was reduced with a monoacylglyceride (MAG)-conjugated form of eicosapentaenoic acid (EPA) supplementation, whereas docosahexanenoic acid (DHA) caused an early reduction. MAG-EPA significantly decreased tumor blood vessel diameter (
Identifiants
pubmed: 33262291
pii: 1541-7786.MCR-20-0316
doi: 10.1158/1541-7786.MCR-20-0316
doi:
Substances chimiques
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-527Informations de copyright
©2020 American Association for Cancer Research.
Références
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8:a030361.
Labbe DP, Uetani N, Vinette V, Lessard L, Aubry I, Migon E, et al. PTP1B deficiency enables the ability of a high-fat diet to drive the invasive character of PTEN-deficient prostate cancers. Cancer Res. 2016;76:3130–5.
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, et al. High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling. Clin Cancer Res. 2018;24:4309–18.
Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018;50:206–18.
Narita S, Nara T, Sato H, Koizumi A, Huang M, Inoue T, et al. Research evidence on high-fat diet-induced prostate cancer development and progression. J Clin Med. 2019;8:597.
Lin PH, Aronson W, Freedland SJ. An update of research evidence on nutrition and prostate cancer. Urol Oncol. 2019;37:387–401.
Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol. 2010;7:442–53.
Moussa H, Nguile-Makao M, Robitaille K, Guertin MH, Allaire J, Pelletier JF, et al. Omega-3 fatty acids survey in men under active surveillance for prostate cancer: from intake to prostate tissue level. Nutrients. 2019;11:1616.
Akinsete JA, Ion G, Witte TR, Hardman WE. Consumption of high omega-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice. Carcinogenesis. 2012;33:140–8.
Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, et al. Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression. Prostate. 2016;76:1293–302.
Gevariya N, Besancon M, Robitaille K, Picard V, Diabate L, Alesawi A, et al. Omega-3 fatty acids decrease prostate cancer progression associated with an antitumor immune response in eugonadal and castrated mice. Prostate. 2019;79:9–20.
Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007;117:1866–75.
Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, et al. Role of host GPR120 in mediating dietary omega-3 fatty acid inhibition of prostate cancer. J Natl Cancer Inst. 2019;111:52–9.
Moreel X, Allaire J, Leger C, Caron A, Labonte ME, Lamarche B, et al. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prev Res. 2014;7:766–76.
Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105:1132–41.
Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173:1429–39.
Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131–40.
Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. Marine- and plant-derived omega-3 fatty acids differentially regulate prostate cancer cell proliferation. Mol Clin Oncol. 2013;1:444–52.
Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, et al. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res. 2011;4:2062–71.
Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MTt, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17:3577–87.
Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, et al. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res. 2014;7:97–104.
Wendler A, Wehling M. The translatability of animal models for clinical development: biomarkers and disease models. Curr Opin Pharmacol. 2010;10:601–6.
Guertin MH, Robitaille K, Pelletier JF, Duchesne T, Julien P, Savard J, et al. Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. BMC Cancer. 2018;18:64.
Superko HR, Superko AR, Lundberg GP, Margolis B, Garrett BC, Nasir K, et al. Omega-3 fatty acid blood levels clinical significance update. Curr Cardiovasc Risk Rep. 2014;8:407.
Zheng H, Tang H, Liu M, He M, Lai P, Dong H, et al. Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Cancer Prev Res. 2014;7:824–34.
Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human “angiogenesis” assays with capillaries formed in vivo. Angiogenesis. 2001;4:113–21.
Dickinson A, Blatman J, El-Dash N, Franco JC. Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr. 2014;33:176–82.
Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, et al. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer. 2009;45:2077–86.
Aucoin M, Cooley K, Knee C, Fritz H, Balneaves LG, Breau R, et al. Fish-derived omega-3 fatty acids and prostate cancer: a systematic review. Integr Cancer Ther. 2017;16:32–62.
Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova((R)) compared to Lovaza((R)) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6:573–84.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018;3:225–34.
Pot GK, Brouwer IA, Enneman A, Rijkers GT, Kampman E, Geelen A. No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr. 2009;63:1353–9.
de Roos B, Geelen A, Ross K, Rucklidge G, Reid M, Duncan G, et al. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics. 2008;8:1965–74.
Ottestad I, Vogt G, Retterstol K, Myhrstad MC, Haugen JE, Nilsson A, et al. Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial. Br J Nutr. 2012;108:315–26.
Van Blarigan EL, Gerstenberger JP, Kenfield SA, Giovannucci EL, Stampfer MJ, Jones LW, et al. Physical activity and prostate tumor vessel morphology: data from the health professionals follow-up study. Cancer Prev Res. 2015;8:962–7.
Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S. Inflammatory signaling involved in high-fat diet induced prostate diseases. J Urol Res. 2015;2:1018.
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019;11:eaau5758.
El Akoum S, Lamontagne V, Cloutier I, Tanguay JF. Nature of fatty acids in high fat diets differentially delineates obesity-linked metabolic syndrome components in male and female C57BL/6J mice. Diabetol Metab Syndr. 2011;3:34.
Pacheco SO, Pacheco FJ, Zapata GM, Garcia JM, Previale CA, Cura HE, et al. Food habits, lifestyle factors, and risk of prostate cancer in central argentina: a case control study involving self-motivated health behavior modifications after diagnosis. Nutrients. 2016;8:419.
Hackshaw-McGeagh LE, Penfold CM, Walsh E, Donovan JL, Hamdy FC, Neal DE, et al. Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. Int J Cancer. 2015;137:1509–15.
Berger V. Selection bias and covariate imbalances in randomized clinial trials. 2005.
Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, et al. Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Mol Cancer Res. 2019;17:949–62.
Witte TR, Salazar AJ, Ballester OF, Hardman WE. RBC and WBC fatty acid composition following consumption of an omega 3 supplement: lessons for future clinical trials. Lipids Health Dis. 2010;9:31.
Morin C, Hiram R, Rousseau E, Blier PU, Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2014;307:H574–86.
Barros KV, Carvalho PO, Cassulino AP, Andrade I, West AL, Miles EA, et al. Fatty acids in plasma, white and red blood cells, and tissues after oral or intravenous administration of fish oil in rats. Clin Nutr. 2013;32:993–8.
Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood. 2008;111:3514–21.
Mukutmoni-Norris M, Hubbard NE, Erickson KL. Modulation of murine mammary tumor vasculature by dietary n-3 fatty acids in fish oil. Cancer Lett. 2000;150:101–9.
Morin C, Fortin S, Rousseau E. Docosahexaenoic acid monoacylglyceride decreases endothelin-1 induced Ca(2+) sensitivity and proliferation in human pulmonary arteries. Am J Hypertens. 2012;25:756–63.
Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR. Vessel co-option in cancer. Nat Rev Clin Oncol. 2019;16:469–93.
Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res. 2007;67:5789–97.
Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001;61:2736–43.
Tomic TT, Gustavsson H, Wang W, Jennbacken K, Welen K, Damber JE. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate. 2012;72:705–12.
Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res. 2005;11:584–93.
Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbo-Jorgensen C, et al. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. Prostate. 2015;75:1682–93.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22.
Franses JW, Baker AB, Chitalia VC, Edelman ER. Stromal endothelial cells directly influence cancer progression. Sci Transl Med. 2011;3:66ra5.